Alimera’s phase-3 trials in DME miss interim efficacy threshold for halt and will continue as planned. <a href="http://biz.yahoo.com/prnews/080924/aqw535.html" target="_blank">http://biz.yahoo.com/prnews/080924/aqw535.html</a>